KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
网页链接KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
网页链接
精彩评论